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distinct ␣-syn strains underlie PD and MSA and offer possible directions for synucleinopathy diagnosis.

Fibrillar ␣-synuclein (␣-syn)4 inclusion bodies define two
major classes of neurodegenerative disease: Lewy body diseases
(Parkinson disease and dementia with Lewy bodies) and those
characterized by Papp-Lantos bodies (multiple system atrophy). These are collectively termed synucleinopathies (1–3).
Synucleinopathies may progress via transcellular propagation
of a unique ␣-syn aggregate conformer, or “seed.” This is analogous to propagation of prion protein (PrP) prions (4 –6). In
this model, the seed escapes one cell and acts as a template in
a secondary cell to trigger further intracellular aggregation
(7–10). In cell culture models, assemblies of ␣-syn trigger their
own uptake and intracellular seeding via endocytosis mediated
by heparan sulfate proteoglycans (11), and may also involve a
cell surface receptor, LAG3 (12). Both in vitro and in vivo evidence supports the concept that ␣-syn is mobile, and that, like a
prion, it can trigger development of pathology upon entry into
second-order cells (13–26).
PrP prion strains are protein assemblies that consist of a defined structure, replicate faithfully in vivo, and produce clinically
and neuropathologically heterogeneous phenotypes (27–34). Although distinct ␣-syn conformers have not yet been fully characterized or propagated through living systems as bona fide strains,
multiple studies suggest they exist (35–39). For a review, see Refs.
40 and 41. This concept applies to synucleinopathies and other
neurodegenerative diseases. We have found distinct conformations of tau will propagate indefinitely and produce predictable
and transmissible pathology upon inoculation (34, 42, 43). Other
groups have found evidence of conformation-dependent patterns
of neuropathology in various ␤-amyloidoses (44–47).
Although Parkinson’s disease (PD) and multiple system atrophy (MSA) are clinically and neuropathologically diverse (48), it
is nonetheless unclear whether patients harbor ␣-syn strains as
4

The abbreviations used are: ␣-syn, ␣-synuclein; PD, Parkinson’s disease;
PDD, Parkinson’s disease dementia; MSA, multiple system atrophy; PrP,
prion protein; CFP, cyan fluorescent protein; A␤, amyloid ␤; Cb, cerebellum; BG, basal ganglia; AC, anterior cingulate gyrus; Am, amygdala; FBS,
fetal bovine serum; BCA, bicinchoninic acid; PBS-T, PBS Tween 20; DAPI,
4⬘,6-diamidino-2-phenylindole; BCA, bicinchoninic acid; TBS, Tris-buffered
saline; ANOVA, analysis of variance.
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Parkinson’s disease (PD) and multiple system atrophy (MSA)
are distinct clinical syndromes characterized by the pathological accumulation of ␣-synuclein (␣-syn) protein fibrils in neurons and glial cells. These disorders and other neurodegenerative diseases may progress via prion-like mechanisms. The prion
model of propagation predicts the existence of “strains” that
link pathological aggregate structure and neuropathology. Prion
strains are aggregated conformers that stably propagate in vivo
and cause disease with defined incubation times and patterns of
neuropathology. Indeed, tau prions have been well defined, and
research suggests that both ␣-syn and ␤-amyloid may also form
strains. However, there is a lack of studies characterizing PDversus MSA-derived ␣-syn strains or demonstrating stable
propagation of these unique conformers between cells or animals. To fill this gap, we used an assay based on FRET that
exploits a HEK293T “biosensor” cell line stably expressing
␣-syn (A53T)-CFP/YFP fusion proteins to detect ␣-syn seeds in
brain extracts from PD and MSA patients. Both soluble and
insoluble fractions of MSA extracts had robust seeding activity, whereas only the insoluble fractions of PD extracts displayed seeding activity. The morphology of MSA-seeded
inclusions differed from PD-seeded inclusions. These differences persisted upon propagation of aggregation to secondgeneration biosensor cells. We conclude that PD and MSA
feature ␣-syn conformers with very distinct biochemical
properties that can be transmitted to ␣-syn monomers in a
cell system. These findings are consistent with the idea that

Distinct conformers of ␣-syn in PD and MSA

characterized by distinct, self-templating conformations that
exhibit unique biochemical characteristics and patterns of cellular pathology. Several groups have used different methods to
generate distinct populations of recombinant ␣-syn fibrils in
vitro (35, 36, 49). However, it is unclear whether these assemblies consist of defined structures that replicate indefinitely
upon transmission between individuals in living systems. Furthermore, the initial assemblies were created from recombinant ␣-syn, and it is unknown whether these conformers exist
in human synucleinopathies. Watts et al. (26) address part of
this question, reporting that homogenates from MSA brain
induce seeding and transmissible pathology in ␣-syn transgenic
mice. Other studies also reported no seeding activity in PD brain
lysate, either in a biosensor cell line or in inoculated animals (37,
38). A recent study by Peng et al. (39) describes biochemical differences in ␣-syn isolated from PDD (Parkinson disease dementia)
and MSA brain, however, evidence of maintenance of strain-specific characteristics through passage is still lacking. To compare
and contrast PD and MSA ␣-syn seeds, we have used an established cell-based assay to test for self-propagating structures that
exhibit unique biochemical characteristics.

fluorescent proteins (␣-syn-CFP/YFP) (50, 51). We determined
empirically that A53T creates the most effective biosensor for
recombinant ␣-syn fibril detection by comparing it to WT
␣-syn (Fig. 1A). Hereafter, we refer to the ␣-syn (A53T) protein
in the biosensor line simply as ␣-syn-CFP/YFP. ␣-Syn-CFP/
YFP does not spontaneously aggregate within cells. But these
cells will take up exogenous recombinant ␣-syn seeds that will
subsequently trigger intracellular aggregation of the ␣-synCFP/YFP biosensor proteins. This can be directly visualized by
epifluorescence microscopy, or quantified via fluorescence resonance energy transfer (FRET) (50, 51). In the FRET flow
cytometry assay, we determined a lower limit for detection of 1
pM (monomer equivalent) recombinant ␣-syn fibrils (Fig. 1B).
Exposure of cells to fibrils prepared from synthetic A␤(1– 42)
and recombinant tau did not generate any signal by FRET flow
cytometry, or visible inclusions via fluorescence microscopy,
even at 10,000-fold over the detection limit for ␣-syn fibrils
(Fig. 1, C and D). Although application of fibrils alone triggered
seeding in the biosensor cells, addition of Lipofectamine
strongly increased seeding (Fig. 1E). Consequently, we used this
agent in our subsequent experiments.

Results
␣-Syn biosensor cells detect seeding activity
To detect ␣-syn seeding activity, we have previously created
biosensor cell lines based on ␣-syn fusion to cyan and yellow

PD and MSA brain extracts contain ␣-syn seeds
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Prior reports have indicated that brain extract from MSA,
but not PD, contains ␣-syn seeding activity (26, 37, 38). We
used the ␣-syn-CFP/YFP biosensor cell line to test for seeding
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Figure 1. FRET-based assay to detect ␣-syn seeding activity. A, dose-response curves generated for seeding activity as measured by the FRET assay with
␣-syn (A53T)-CFP/YFP and (WT)-CFP/YFP biosensors in response to seeding with recombinant WT synuclein fibrils in transiently transfected cells. B, doseresponse for recombinant ␣-syn fibrils. Stable cells expressing the ␣-syn (A53T)-CFP/YFP biosensor were exposed to increasing amounts of ␣-syn fibrils in the
presence of Lipofectamine, and induced aggregation was quantified using FRET flow cytometry. Detectable conversion occurred at 1 pM fibrils (monomer
equivalent); *, p ⬍ 0.007. C, ␣-syn-CFP/YFP biosensor cells are specific for ␣-syn. 10 nM ␣-syn fibrils produce robust seeding (**, p ⬍ 0.0001), but not 100 nM
A␤(1– 42) or 100 nM tau fibrils. D, fluorescence images of induced ␣-syn-CFP/YFP inclusions. Images are at ⫻40 magnification with scale bars of 25 m.
Arrowhead indicates inclusion within biosensor cell. E, Lipofectamine enhances ␣-syn seed detection in the FRET biosensor assay as measured at 100 nM
concentration of recombinant ␣-syn fibrils (*, p ⬍ 0.001, t test compared with vehicle-treated condition).

Distinct conformers of ␣-syn in PD and MSA

activity in postmortem brain tissue from both PD (n ⫽ 5) and
MSA (n ⫽ 5) cases. We evaluated regions previously determined to have abundant ␣-syn pathology based on histopathological analyses by a neuropathologist (N. J. C.). In PD, the anterior cingulate gyrus (AC) and amygdala (Am) contain high
levels of neuronal ␣-syn pathology, including Lewy bodies and
Lewy neurites (Fig. 2A). In MSA, the cerebellum (Cb) and basal
ganglia (BG) exhibit abundant inclusions (Papp-Lantos bodies)
in oligodendrocytes and in white matter tracts (Fig. 2A). Neuropathological characteristics of all PD, MSA, and control
patients are detailed in Table 1. Prior to the analysis of seeding

activity using the FRET biosensor system, we sequentially
extracted tissue samples according to previously described
methods (52). We began with homogenization in high salt
buffer without detergent, followed by ultracentrifugation at
100,000 ⫻ g to generate the “buffer-soluble” fraction. We then
homogenized the pellet in buffers containing 1% Triton X-100,
with a wash step, followed by ultracentrifugation at 100,000 ⫻ g
to generate the “detergent-insoluble” fraction (see “Experimental procedures” for details). The detergent-insoluble fractions
of both PD and MSA contained ␣-syn seeding activity detected
by the FRET biosensor assay, with higher levels in MSA brain
J. Biol. Chem. (2019) 294(3) 1045–1058
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Figure 2. ␣-Syn seeding from insoluble and soluble fractions of PD and MSA brain. A, microscopy of PD, MSA, and normal control brains used in the
seeding experiments. Scale bar ⫽ 100 m. Patient samples are displayed as follows: PD#4 AC, PD#4 Am, MSA#4 Cb, MSA#4 BG, Control#2 AC, Am, Cb, and BG.
B, seeding detected from insoluble fractions of PD anterior cingulate and amygdala. Controls are 10 nM recombinant fibril (⫹) and buffer only (⫺) samples. C,
seeding detected from insoluble MSA cerebellum and basal ganglia fractions. D, control insoluble brain samples from matched regions exhibit no appreciable
seeding. Note: no amygdala sample was available for PD1 from the autopsy bank. *, p ⬍ 0.004, t test compared with vehicle-treated condition. E, PD soluble
fractions did not demonstrate significant seeding activity other than PD5, which is significant, p ⫽ 0.0003 on t test compared with vehicle-treated conditions
(post-hoc Bonferroni correction is 0.0028 for n ⫽ 19 comparisons). F, MSA-soluble fractions contain significant seeding activity. *, p ⬍ 0.0006, t test compared
with vehicle-treated conditions. G, soluble fractions from region-matched control samples do not demonstrate any significant seeding.

Distinct conformers of ␣-syn in PD and MSA
TABLE 1
Clinical and neuropathological characteristics of brain samples for
synucleinopathy and non-synucleinopathy controls
Control samples were selected to match MSA and PD samples for a range of tau and
amyloid pathology patterns. DLBD, diffuse lewy body disease; *, MSA-nigrostriatal
type; ADNC, Alzheimer disease neuropathologic change; AGD, argyrophilic grain
disease; TDP-MTL, TDP-43 proteinopathy in medial temporal lobe; ALS, amyotrophic lateral sclerosis; PART, primary age-related tauopathy.

1048 J. Biol. Chem. (2019) 294(3) 1045–1058

MSA and PD seeds produce distinct inclusion morphologies
Prionopathies produce unique clinical and neuropathological syndromes depending upon the conformation, or
strain, of the PrP prion (27, 29). In tauopathies, distinct tau
strains correlate with specific neurodegenerative diseases,
and exhibit clear differences in inclusion morphology within
cultured cells that correlate with (but do not morphologically match) unique biochemical profiles and induction of
different types of tauopathy in vivo (42). In synucleinopathies, the classic neuropathological hallmark of PD, the
intraneuronal Lewy body, differs morphologically from the
Papp-Lantos body seen in oligodendroglia in MSA. Given
the differences we observed in the solubility of seeding activity derived from PD versus MSA brains, and prior reports
about the failure of PD brain extracts to seed in vitro and in
vivo (26, 37, 38), we hypothesized that ␣-syn might exhibit
properties of classical prion strains. We thus tested whether
seeding from PD versus MSA brains would produce distinct
inclusion patterns in the biosensor cells.
We exposed biosensor cells to recombinant ␣-syn fibrils, or
fractions from PD and MSA brains, and examined inclusions by
fluorescence microscopy (Fig. 4A). We observed no visible
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tissue samples (Fig. 2, B and C). Seeding activity correlated
between regions for each of the patients examined, i.e. brains
with high seeding in amygdala also had high seeding in the
anterior cingulate, and vice versa. We obtained control brain
samples from identical regions of patients with similar degrees
of Alzheimer disease neuropathology (53) (Table 1). None of
these control brain samples contained appreciable levels of
␣-syn seeding activity (Fig. 2D).
Given the sensitivity of the biosensor assay, we tested for
differences in the level of soluble ␣-syn seeding activity. We
detected robust seeding activity from the soluble fractions of
almost all MSA brain samples (Fig. 2F), whereas we detected
almost none in all PD brain samples (Fig. 2E). Soluble fractions
from controls had no appreciable seeding activity (Fig. 2G).
Taken together, we conclude that seeding activity in PD consists predominantly of detergent-insoluble species, whereas in
MSA it consists of both detergent-soluble and -insoluble forms.
Given the observed differences in seeding activity of PD and
MSA, we measured ␣-syn levels in the insoluble fractions by
enzyme-linked immunosorbent assay (ELISA) (52). For capture, we used Syn211 antibody (Santa Cruz), which binds near
the C terminus of ␣-syn (amino acids 121–125). For detection,
we used a polyclonal antibody FL-140 (Santa Cruz). We
detected higher ␣-syn levels in synucleinopathy cases versus
controls. We detected higher levels of total ␣-syn in PD-insoluble samples than MSA-insoluble samples (Fig. 3, A versus B).
We found the lowest level of ␣-syn in control groups (Fig. 3C).
␣-Syn concentration in insoluble samples and seeding activity strongly correlated within each disease state. That is, insoluble fractions of PD with higher concentrations of total ␣-syn
by ELISA demonstrated more seeding activity (Fig. 3D). There
was a similar observation for insoluble fractions of MSA (Fig.
3E). One sample in each set of PD and MSA brains had no
detectable seeding activity (Fig. 2, B and C). This correlated
with lower levels of ␣-syn as measured in insoluble fractions by
ELISA (Fig. 3, A and B) and immunoblot (Fig. 3, G and H) for
both regions surveyed.

Comparing seeding activity relative to ␣-syn concentration
between disease states, we observed higher seeding activity per
ng of insoluble ␣-syn in MSA versus PD brain (p ⫽ 0.0202, r ⫽
0.7333 for MSA, and p ⫽ 0.0017, r ⫽ 0.8802 for PD by Spearman analysis) (Fig. 3, D and E). Control samples did not show a
similar correlation (p ⫽ 0.7343, r ⫽ 0.1044) (Fig. 3F). We verified ELISA results by immunoblot for total ␣-syn (Clone 42, BD
Bioscience), which confirmed lower levels of total ␣-syn in
MSA- versus PD-insoluble fractions, as well as minimal ␣-syn in
control insoluble fractions (Fig. 3, G–I) as determined by band
density relative to recombinant monomer (Fig. 3, J–L).
Immunoblots for ␣-syn in soluble fractions (utilizing
Clone42 antibody) revealed relatively less total ␣-syn in
MSA than PD (Fig. 3, M and N) and the presence of ␣-syn in
soluble fractions from control samples, as expected (Fig. 3O).
Given the lack of robust seeding activity seen in PD soluble
samples (Fig. 2E), soluble seeding activity in PD did not
depend on soluble ␣-syn concentration as measured by
immunoblot (Fig. 3M). The one PD brain sample with
detectable soluble seeding activity did not show significantly
higher levels of soluble ␣-syn (Fig. 3M).
Phosphorylated forms of ␣-syn have been associated
with pathogenicity in synucleinopathies (43). To determine
whether phosphorylated ␣-syn was present in our fractions,
and whether it correlated with seeding activity, we performed immunoblots for pSer-129 (EP1536Y, Abcam) in
both insoluble and soluble fractions from MSA, PD, and control brain samples. Insoluble fractions from both PD and
MSA demonstrated phosphorylation of ␣-syn (although PD
was more consistent in this regard) (Fig. 3, P and Q), whereas
insoluble control extracts and all soluble fractions, even soluble MSA extracts, did not contain detectable levels of phosphorylated ␣-syn (Fig. 3, R–U). Thus, seeding activity of
␣-syn derived from brain tissue did not relate to the pSer129 phosphorylation state.

Distinct conformers of ␣-syn in PD and MSA
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Figure 3. PD and MSA total and phosphorylated ␣-syn levels. A–C, ␣-syn concentration as measured by ELISA in PD-, MSA-, and Control-insoluble extracts
(g/ml). D–F, scatterplot of ␣-syn seeding activity detected by FRET assay compared with total concentration of ␣-syn measured by ELISA. Correlation
coefficients as calculated by Spearman nonparametric two-tailed analysis: (PD, p ⫽ 0.0017, r ⫽ 0.8802; MSA, p ⫽ 0.0202, r ⫽ 0.7333; Control, p ⫽ 0.7343, r ⫽
0.1044). G–I, immunoblot for total ␣-syn from brains of PD, MSA, and Control patient-insoluble extracts. J–L, relative band density as determined by comparison
to equivalent concentrations of ␣-syn WT fibrils loaded on same blots. M–O, immunoblot for total ␣-syn from soluble extracts. P–R, Western immunoblot
detects phosphorylated ␣-syn in insoluble extracts of PD and MSA but not in control insoluble extracts. S–U, no phosphorylated ␣-syn is detected in soluble
extracts.

inclusions in Lipofectamine-treated controls, whereas recombinant ␣-syn fibrils produced distinct inclusions. We did not
observe inclusions induced by soluble PD brain fractions, as
reported above. However, detergent-insoluble PD brain extract
produced uniformly smaller and more circumscribed inclusions. MSA-insoluble and soluble-brain extract produced
filamentous, wispy inclusions that filled the cytoplasm. The

induced inclusion morphologies correlated with disease, not
brain region, and soluble and insoluble material from MSA
brains produced indistinguishable patterns. Inclusions were
cytoplasmic, as demonstrated by confocal microscopy with a
nuclear stain (DAPI) (Fig. 4, B and C). Distinct morphological
characteristics were consistent across all brain samples that
produced inclusion formation (Fig. 4C).
J. Biol. Chem. (2019) 294(3) 1045–1058
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To further characterize inclusions and determine whether
there is similarity to pathologic ␣-syn found within patient
brains, we performed immunocytochemistry on seeded biosensor cells. Inclusions exhibited amyloid structure based on colocalization with amyloid dye X34 (Fig. 5A). Inclusions were
colocalized with p62/SQSTM1 staining (ab56416, Abcam), a
marker for polyubiquitinated protein aggregates (Fig. 5B) and
pSer-129 antibody P-syn/81A (Biolegend) (Fig. 5C). Pearson
correlation coefficients indicated significant co-localization
(p ⬍ 0.0001 one-way ANOVA with Dunnett multiple comparison test to control condition) of the X34, p62/SQSTM1, and
pSer-129 stain with PD-insoluble and MSA-insoluble and -soluble aggregates (Fig. 5, D–F). Pearson correlation values may
underestimate co-localization because brain-derived ␣-syn
added to cells may also bind these antibodies but would not
necessarily co-localize with the GFP signal.
Induction of inclusion morphology in second-generation cells
PrP prion strains always produce the same patterns of cellular pathology and disease incubation times in vivo (29, 31), and
tau strains have similar properties (42). We thus tested whether
␣-syn aggregates induced in the biosensor cells by PD or MSA
brain extracts would faithfully pass the same inclusion morphologies to second-generation cells. We first exposed biosensor cells to MSA or PD brain extracts. We incubated the cells
(G1 population), for 72 h, and serially extracted the ␣-syn-CFP/

1050 J. Biol. Chem. (2019) 294(3) 1045–1058

YFP as described above in our studies of brain tissue samples.
We then used these fractions to seed a naive population of biosensor cells (G2 population) using visual inspection for inclusion formation (Fig. 6A). Insoluble fractions of PD- and MSAseeded biosensor cells induced inclusions with the same
inclusion morphologies seen in the original seeded cells (Fig.
6B). Furthermore, consistent with prior seeding experiments
(Fig. 2), MSA-seeded cells developed inclusions from the soluble and insoluble cell lysate fractions, whereas PD-seeded cells
only developed inclusions from the insoluble material (Fig. 6B).
To test the degree to which inclusion formation derived from
induction of ␣-syn aggregation within biosensor cells versus
persistence of brain-derived ␣-syn, we seeded HEK293T cells
that lack ␣-syn overexpression with brain tissue in parallel with
biosensor cells, prior to identical extraction. For insoluble PD
material, this induced seeding at about 60% of that from lysates
passaged through biosensor cells, and 17% for insoluble MSA
material. Soluble MSA material passaged through control cells
had 0% background (Fig. 6C).
Passage of proteopathic ␣-syn through an in vivo system
could potentially amplify these pathogenic forms. To determine whether ␣-syn concentrations or phosphorylated ␣-syn
levels changed with passage through the biosensor cells, we
performed immunoblots on G1 and G2 cell extracts (Fig. 6,
D–G). All immunoblots demonstrated a species at ⬃42 kDa
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Figure 4. MSA and PD induce inclusions of distinct morphology. A, biosensor cells seeded with buffer (Opti-MEM) and Lipofectamine reagent only, 10 nM
recombinant ␣-syn fibrils, or insoluble extracts from PD (patient #5) anterior cingulate, PD#4 amygdala, MSA#4 cerebellum, and MSA#5 basal ganglia. Arrows
indicate typical aggregates within cells; circumscribed morphology from PD brain tissue and wispy morphology seen in MSA brain tissue. Scale bars are 25 m.
B, confocal pictures from cells seeded with buffer (Control) and 10 nM recombinant ␣-syn fibrils and counterstained with DAPI. Scale bars on all confocal pictures
are 25 m. C, confocal pictures from each brain sample demonstrate consistent morphological differences between aggregates seeded from PD-insoluble
extracts and MSA-soluble and -insoluble extracts. Soluble PD fractions did not produce aggregates as expected. Scale bars are 10 m.

Distinct conformers of ␣-syn in PD and MSA

corresponding to the ␣-syn-CFP/YFP fusion proteins constitutively expressed within the biosensor cells. MSA-derived samples and to a lesser extent, PD-derived fractions, demonstrated
oligomeric forms in insoluble fractions, whereas control fractions and buffer-seeded cells did not show oligomeric banding
patterns (Fig. 6, D and E). Phosphorylated forms were also more
prevalent in the G1 and G2 MSA-insoluble fractions. We
observed an increase in phosphorylated forms of ␣-syn in the
MSA samples over sequential passage, especially in the soluble fractions (Fig. 3, M and N, versus Fig. 6, E and G). Taken
together we conclude that ␣-syn seeds derived from PD or MSA
brain induce ␣-syn-CFP/YFP aggregation transmissible in biosensor cells that parallels the solubility and morphological patterns observed within human brain samples.

Discussion
The origins of distinct ␣-syn-related diseases such as PD and
MSA are unknown. One possibility is that distinct conformations, or “strains” of ␣-syn cause different disorders. Prior work
has not isolated seeding activity from PD brains, however, and
thus it has not been possible to directly compare PD-derived
seeds to those of MSA. In this study we used a sensitive and
specific FRET biosensor assay based on expression of ␣-synCFP/YFP containing the SNCA A53T mutation to detect ␣-syn
seeding activity. We quantified the activity present in solubleand detergent-insoluble brain fractions. Although both PD and
MSA brains contained insoluble seeding activity, only MSA
brain contained soluble activity. We further observed that PD

and MSA ␣-syn seeds induced distinct inclusion morphologies
and detergent solubility of aggregates in biosensor cells. Finally,
upon transduction of brain lysates into biosensor cells, the
induced aggregates exhibited detergent solubilities similar to
those of ␣-syn seeds present in PD and MSA brains and created
identical inclusion morphologies in a second generation of
cells. Within the limitations of our studies, isolation and characterization of two forms of ␣-syn that are linked directly to PD
and MSA is consistent with the existence of distinct ␣-syn
strains.

␣-Syn biosensor assay
The biosensor assay described here used full-length ␣-syn
(A53T) fused to CFP or YFP (␣-syn-CFP/YFP), and was originally reported in a prior publication (50). We easily observed
seeding of the ␣-syn-CFP/YFP reporter by recombinant wildtype (WT) ␣-syn fibrils, which has been reported in vitro (54).
This cell-based assay allows quantification of aggregation in a
population of cells by flow cytometry utilizing a distinct FRET
signal, whereas single-fluorophore quantification of inclusions
requires direct microscopy counts (38). Prior work has indicated that tau and ␣-syn biosensors are highly specific to the
origin of seeds (42, 50), and in this study we also tested control
samples from advanced AD cases (Braak Stage VI) that contained high levels of tau and A␤ pathology. We found no evidence of “cross-seeding” of ␣-syn by tau or A␤. Although a
prior report suggested that exposure of neurons in culture to
␣-syn fibrils “cross-seeds” tau (35), we have not observed any
J. Biol. Chem. (2019) 294(3) 1045–1058
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Figure 5. Intracellular inclusions demonstrate colocalization with markers for aggregation. A, biosensor cells seeded with PD, MSA, recombinant fibrils
all demonstrated inclusions which colocalize with X34 staining. 0 is buffer-seeded, fibril is 10 nM recombinant ␣-syn fibril, PD INS is PD patient #4 anterior
cingulate-insoluble fraction, MSA INS is MSA patient #5 basal ganglia-insoluble fraction, MSA SOL is patient #5 basal ganglia soluble fraction. B, inclusions were
similarly positive for p62/SQSTM1 (PD INS (#4 amygdala), MSA INS (#4 basal ganglia), and MSA SOL (#4 basal ganglia)). C, pSer-129 staining was similarly positive
(PD INS (#4 amygdala), MSA INS (#4 basal ganglia), and MSA SOL (#5 basal ganglia)). All scale bars are 10 m. Arrowheads demonstrate colocalization of
inclusions with respective markers. Pearson correlation for CFP/YFP and (D) X34, (E) p62/SQSTM1, and (F) pSer-129, *, p ⬍ 0.0001 via one-way ANOVA with
Dunnett’s multiple comparison to 0 (control).
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evidence that ␣-syn or tau seeds heterologous monomer in cells
(42, 50).
In our cell-based assay, cationic lipid reagent (Lipofectamine) enhanced signal, presumably by increasing the
efficiency of seed delivery. In vivo studies have noted uptake
and spreading of injected forms of ␣-syn within the brain
without additional reagents, but in cultured non-neural cells
we have consistently observed a potentiating effect of Lipofectamine in seed delivery (50). This may reflect differences
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in cell surface glycoproteins. Nonetheless, as all samples
were treated identically, we feel confident attributing our
findings to differences in seeding activity in PD versus MSA
samples.

␣-Syn seeding activity detected in both PD and MSA brains
Prior reports have indicated failure to detect ␣-syn seeding
activity in PD brain samples (26, 37, 38). The FRET-based biosensor used here easily detected seeding activity and inclusions
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Figure 6. Preservation of inclusion morphology upon conversion of second-generation cells. A, experimental paradigm. Biosensor cells were
seeded with insoluble or soluble extracts from MSA or PD brain. After 3 days, seeded cells were extracted and soluble and insoluble fractions obtained.
These cell extracts were used to seed naive biosensor cells, and after an additional 3-day incubation, cells were assessed by fluorescence microscopy for
inclusions. B, biosensor cells seeded with insoluble or soluble cell extract from a population of cells initially seeded with insoluble or soluble extract from
PD or MSA brain. Note the preservation of inclusion morphology, and pattern of seeding that correlates with that seen from brain tissue-seeded cells.
Image magnification was ⫻40, scale bar 25 m. Images include PD sol/sol, patient #4 amygdala; PD insol/insol, #5 amygdala; MSA sol/sol, #5 cerebellum;
MSA insol/insol ⫽ #4 basal ganglia. C, control HEK293T cells that lack ␣-syn overexpression or biosensor cells overexpressing ␣-syn (A53T)-CFP/YFP (G1),
were seeded with brain extract (MSA or PD) and serially extracted after a 3-day incubation period. Soluble and insoluble cell extracts were used to seed
biosensor cells (G2). After addition of exogenous seeds, biosensor cells expressing ␣-syn efficiently propagate seeding activity and inclusion morphology to second-generation biosensor cells (G2). HEK293T cells that lack ␣-syn overexpression propagate pathology inefficiently due to residual seeds
carried over through them. Seeding activity in all fractions passaged more efficiently through biosensor cells than through HEK293 cells. *, p ⫽ 0.0005
t test. Results were replicated by two different methods (flow cytometry and histological cell counts) for two regions from two different PD patient brains
(#4 and #5 anterior cingulate and amygdala) and two regions from two different MSA patient brains (#2 and #3, cerebellum and basal ganglia). D and E,
G1- and G2-seeded cells were serially extracted and fractions run on immunoblot showing total ␣-syn. There are aggregated forms of ␣-syn in
MSA-insoluble fractions, but not in PD or control samples. P ⫽ PD, M ⫽ MSA, Cn ⫽ Control tissue, A ⫽ anterior cingulate, C ⫽ cerebellum, B ⫽ basal
ganglia, Y ⫽ amygdala, 0 ⫽ buffer seeded negative control, and F ⫽ recombinant fibril seeded control (10 nM). F and G, G1- and G2-seeded cells were
serially extracted and ␣-syn assessed by Western blotting for phosphorylated forms of ␣-syn. Phosphorylated ␣-syn levels and also aggregated forms
of phosphorylated ␣-syn were higher in MSA than in PD in both soluble and insoluble forms.
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␣-Syn strains in PD and MSA
Evidence that ␣-syn strains account for different synucleinopathies is still incomplete. Recombinant assemblies created
in vitro by serial seeding reactions show distinct toxicities,
induction of pathology, and biochemical differences after passage in vivo (35, 36). However, as it is very difficult to amplify a
single fibrillar conformation in vitro, these ␣-syn assemblies
might have been of heterogeneous composition, and do not
necessarily reflect those produced during the life of the patient.
Prior work has described ␣-syn seeding activity of MSA brain
extracts, but left in question whether PD extract actually contains any seeding activity (26, 37, 38). Our work is consistent
with a recent study that has found biochemical-based differences between Sarkosyl-extracted ␣-syn from PDD and MSA
brain (39). However, there is still a lack of convincing evidence
that strain-specific properties are maintained after passage
through in vitro or in vivo systems. In this study we used a
biosensor cell line to determine that brain extracts from both
PD and MSA contain ␣-syn seeding activity. Both diseases had
seeding activity in detergent-insoluble brain fractions, but MSA
also had such activity in the detergent-soluble fraction. This
suggests a possible explanation for the failure of several prior
studies to detect seeding activity in PD brain. Although we
detected lower levels of total ␣-syn in MSA versus PD by two
different biochemical methods, we observed much more robust
seeding activity in MSA. This was most evident in soluble fractions. ELISA and immunoblot data both indicate that total levels of ␣-syn do not necessarily predict seeding ability of samples, especially in MSA-soluble samples. Seeding ability of
␣-syn derived from brain also does not seem dependent on
pSer-129 ␣-syn, suggesting that while this post-translational
modification is an important pathological marker, it may not be
necessary for seeding ability of ␣-syn.
We propose that the seeding activity in MSA may be inherently distinct from PD. This is consistent with other studies that

have only found seeding activity in MSA (26, 37, 38). PD and
MSA brain extracts also produced different inclusion morphologies in biosensor cells. Distinct inclusion morphologies imply,
but do not prove, that underlying fibril structure differs. However, inclusion morphology across brain regions and patient
samples for PD versus MSA was strikingly consistent. These
different morphologies were associated with the same detergent solubility profiles observed in human brain. We also
observed faithful preservation of inclusion morphologies upon
inoculation of a new population of cells.
Immunoblots of ␣-syn demonstrate insoluble ␣-syn-CFP/
YFP in fractions from cells seeded with soluble PD brain extract
and soluble control brain extract, although corresponding
inclusions are not detected in these fractions by flow cytometry
FRET signal. One possibility is that a low level of aggregation
occurs in unseeded ␣-syn-CFP/YFP cells that is present in the
insoluble fraction but is below the level of detection on the
FRET assay. A second explanation would be that a portion of
insoluble ␣-syn does not fluoresce in this system and is not
detected on FRET flow cytometry. In this last case, FRET may
underestimate the amount of aggregation that occurs from
␣-syn seeding. A third possibility would be carryover of monomeric forms of ␣-syn in the insoluble fraction, in which case the
insoluble fraction would not solely contain aggregated forms of
␣-syn. This is partially supported by low levels of insoluble
␣-syn seen in immunoblots from control brain tissue, which
would not be expected to have aggregated forms of ␣-syn and
does not have FRET activity. It should also be noted that the
presence of insoluble ␣-syn does not necessarily equate with
seeding activity, and the seed-competent component may only
comprise a small fraction of the total insoluble ␣-syn pool. Further experiments will be necessary to define the species that
induce ␣-syn aggregation.
Although it seems likely that ␣-syn strains exist, no study,
including this one, has indefinitely propagated patient-derived
seeds from cell-to-cell, or mouse-to-mouse, or fully characterized ␣-syn strains from MSA versus PD. Indeed, we have failed
to propagate distinct ␣-syn conformers in clonal lines as we
have done for tau (42, 43) because aggregate-containing clones
lose the aggregated state over time. To confirm the existence of
bona fide ␣-syn prion strains, it will be necessary to test whether
distinct structures stably propagate through living systems and
produce consistent pathology, as do tau and PrP. Taken
together with prior studies by others, however, our findings are
very consistent with the existence of different ␣-syn strains in
PD and MSA.

Experimental procedures
Recombinant ␣-syn purification and fibrillization
Recombinant ␣-syn monomer was produced as previously
described (52). Purified recombinant ␣-syn fibrils were generated from incubation of monomer (2 mg/ml) for 72 h at 37 °C
with shaking (1000 rpm) in buffer (20 mM Tris-HCl, pH 8, and
100 mM NaCl). After centrifugation at 15,000 ⫻ g for 15 min,
the concentration of monomer in the supernatant was determined by bicinchoninic acid (BCA) assay (Micro BCA Protein
Assay Kit, ThermoScientific) and the measured decrease in
J. Biol. Chem. (2019) 294(3) 1045–1058
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of distinct morphology from both PD and MSA brains. Several
factors may explain these differences. First, we evaluated material from different patients and different brain regions. We
examined the amygdala and anterior cingulate gyrus, regions
noted to have high levels of phosphorylated ␣-syn, whereas
prior work evaluated substantia nigra and surrounding midbrain, which typically have severe neuronal loss and low levels
of synucleinopathy, at least in advanced cases. The prior studies
also used phosphotungstate anion to precipitate ␣-syn, according to a prior published method (55), whereas we used detergent fractionation.
Immunoblots for phosphorylated ␣-syn from brain tissuesoluble fractions did not show detectable levels in either PD or
MSA, although these same MSA samples were able to seed
aggregation within the ␣-syn-CFP/YFP cells. This suggests that
phosphorylated ␣-syn, whereas a reliable marker for pathology,
does not necessarily correlate with seeding ability. We did see
higher levels of phosphorylated ␣-syn after propagation in our
cell system and isolation, which was especially prominent in
MSA samples. PD and MSA, as well as recombinant synthetic
␣-syn fibril, induced aggregate formation within biosensor cells
that colocalized with pSer-129 staining.

Distinct conformers of ␣-syn in PD and MSA
monomer was used to determine the concentration of fibrils in
the pellet.
Preparation of A␤(1– 42) and tau fibrils

Generation of stable cell lines
Stable cell lines were generated as previously described (50).
HEK293T cells were plated at 150,000 cells/well and subsequently transduced with ␣-syn (A53T)-CFP and ␣-syn (A53T)YFP lentiviral constructs. After 48 –72 h cells were resuspended
in flow buffer and sorted by FACS (Sony Biotechnology)
to select a polyclonal population of dual ␣-syn-CFP/YFP–
expressing cells with a donor:acceptor molar ratio of 1:1.
Median fluorescence intensity ratio of CFP:YFP was (1:2.5) in
this CFP/YFP population. Populations of cells expressing either
␣-syn (A53T)-CFP or ␣-syn (A53T)-YFP were also isolated and
selected as single positive controls. Dual positive cells were
expanded, and subsequently diluted onto 10-cm2 dishes. Single
colonies were selected with cloning cylinders (Bel-Art Products) and expanded. All FRET and fluorescence microscopy
experiments in this paper utilized a monoclonal cell line as the
␣-syn-CFP/YFP biosensor.
Preparation of soluble and insoluble fractions from
postmortem brain tissue
The Movement Disorders Center Neuropathology Core,
Washington University, St. Louis, MO, provided clinically and
neuropathologically well-characterized postmortem frozen
brain tissue (57). Routinely, microscopy was performed on the
left hemibrain and biochemistry was performed using the right
hemibrain. ␣-Syn-immunoreactive inclusion bodies were
observed only in PD and MSA utilizing phosphor-dependent
anti-␣-syn immunohistochemistry (Cell Applications, San
Diego, CA) and #64 (Wako, Osaka, Japan, respectively). Frozen
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FRET seeding assay
Monoclonal biosensor cells were plated in 96-well plates
at 35,000 per well and grown overnight. The following day,
recombinant fibrils or brain lysate fractions were sonicated for
3 min at 65A (Qsonica 700) at 4 °C. Samples were prepared in
Opti-MEM (Gibco) with 1 l of Lipofectamine 2000 (Invitrogen) to a total volume of 20 l/well and incubated at room
temperature for 30 min. Samples were then added dropwise to
wells. Technical quadruplicates were performed for each sample. For samples testing brain lysate, 5 l of soluble or insoluble
material was added per well. Unless otherwise specified, incubation was for 72 h. Cells were then trypsinized and transferred
to 96-well round-bottom plates, fixed in 4% paraformaldehyde
(Electron Microscopy Services) in PBS for 10 min, then centrifuged and resuspended in flow buffer (1 mM EDTA and 1% FBS
in Hank’s balanced salt solution). Finally, they were assessed for
aggregate load using a MACSQuant VYB (Miltenyi) as previously described (50). Analysis was performed using FlowJo v10
software (TreeStar).
Transient transfection experiments were conducted as
described above with the exception of an initial plating step into
12-well plates at 285,000 cells/well followed by transfection
with 4 l of Lipofectamine per well with 250 ng/well of ␣-syn
WT- or mutation A53T-CFP/YFP constructs in a FM5 plasmid,
a modified version of the plasmid as described in Ref. 59. This
was followed by replating of cells into 96-well plates and transfection of recombinant fibrils or brain lysate 1 day later.
Cell immunofluorescence
Glass coverslips were coated with poly-D-lysine hydrobromide (Sigma) overnight at room temperature in 24-well plates,
then washed 3 times with sterile water and allowed to air-dry
for 2 h. Cells were plated at 50,000 cells/well. Cells were transduced the next day with 10 nM fibrils or 35 l of insoluble or
soluble brain fractions with Lipofectamine (3 l/well). For
experiments comparing seeding in HEK cells not overexpressing ␣-syn with biosensor cells expressing ␣-syn-CFP/YFP, after
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Synthetic A␤(1– 42) and tau fibrils were produced according
to published methods (52, 56). 1 mg of synthetic A␤(1– 42) was
dissolved in 50 l of DMSO. Then, 925 l of distilled deionized
H2O with 25 l of 1 M Tris-HCl, pH 7.6, was added and the
reaction mixture was incubated for 30 h at 37 °C with shaking at
1,000 rpm in an Eppendorf Thermomixer. To determine the
concentration of fibrils, the fibril reaction mixture was centrifuged at 15,000 ⫻ g for 15 min to separate fibrils from monomer. The concentration of A␤(1– 42) monomer in the supernatant was determined in a BCA protein assay along with a BSA
standard curve. The measured decrease in monomer concentration was used to determine the concentration of A␤␤(1– 42)
fibrils in the 30-h fibril reaction mixture.
Purified recombinant tau monomer (300 g/ml) in 20 mM
Tris-HCl, pH 8.0, 100 mM NaCl, 25 M low molecular weight
heparin, 0.5 mM DTT was incubated for 48 h at 37 °C with
shaking at 1,000 rpm in an Eppendorf Thermomixer. To determine the concentration of fibrils, the fibril reaction mixer was
centrifuged at 15,000 ⫻ g for 15 min to separate fibrils from
monomer. The concentration of tau monomer in the supernatant was determined in a BCA protein assay along with a BSA
standard curve. The measured decrease in monomer concentration was used to determine the concentration of tau fibrils in
the 48-h fibril reaction mixture.

tissue was prepared as previously described (52, 58). Tissue was
first dissected into small pieces (⬃1 mm square) using a scalpel
and a cutting board cooled with solid CO2. Tissue was then
weighed and serially extracted with a series of buffers, using a
Dounce homogenizer (Kontes) for homogenization. A ratio of 3
ml of buffer to 1 g of tissue was maintained throughout the
extraction process. Initial homogenization was performed in
high salt buffer (50 mM Tris-HCl, pH 7.4, 750 mM NaCl, 5 mM
EDTA) with protease inhibitors (Sigma), followed by centrifugation at 100,000 ⫻ g for 20 min at 4 °C. Supernatant was
removed and used as the buffer “soluble” fraction for further
experiments. The pellet was homogenized in 1% Triton X-100
in high salt buffer with protease inhibitors, followed by centrifugation at 100,000 ⫻ g for 20 min at 4 °C. The pellet was
extracted with 1 M sucrose and 1% Triton X-100 in high salt
buffer. The myelin component and supernatant were removed,
and the pellet was then washed twice with Tris-buffered saline
(TBS), resuspended in TBS, with protease inhibitor (Sigma),
aliquoted, and frozen at ⫺80 °C and used as the detergent
“insoluble” fraction.
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Immunofluorescence and X34 staining
Cells were plated on glass coverslips precoated with poly-Dlysine, seeded with brain tissue or recombinant fibrils, and fixed
with 4% paraformaldehyde as above, then rinsed 3 times for 5
min each in PBS. For immunofluorescent stains, cells were
incubated in 0.1% Triton X-100 in PBS for 15–20 min at room
temperature. For SQSTM1/p62 (Abcam) cells were blocked in
3% normal goat serum (Invitrogen) for 20 min and then incubated in primary antibody 1:100 with 1.5% normal goat serum
overnight at 4 °C. For pSer-129 staining, cells were blocked in
3% FBS with 3% BSA for 1 h at room temperature. Primary
antibody was P-syn/81A (Biolegend), 1:5000, and cells were
incubated in 3% BSA overnight at 4 °C. Subsequently, they were
washed 3 times for 5 min each with PBS then incubated with
secondary antibody (either anti-mouse Alexa Fluor 647 or antirabbit Alexa Fluor 647) 1:500, Jackson ImmunoResearch) for 1
(SQSTM1/p62) or 2 h (P-syn/81A) at room temperature. After
another three washes for 5 min each, the coverslips were
mounted on slides with Fluoromount G (Southern Biotech).
For X34 staining, cells were incubated in 0.25% Triton X-100 in
PBS for 30 min at room temperature. X34 (Sigma) was dissolved
in a staining buffer of 60% PBS, 38% ethanol, and 0.02 M NaOH
to a stock concentration of 1 mM. This was further diluted in
PBS to a 2 M concentration and cells were stained at room
temperature for 15 min. Samples were rinsed three times for 5
min each in PBS then mounted in Fluoromount (Southern Biotech). For confocal microscopy, cells were imaged on Nikon C2
Plus confocal laser system coupled to a Nikon Eclipse Ti microscope. Images were acquired utilizing a Nikon PlanApo oil
immersion objective with numerical aperture of 1.45 and resolution of ⫻100 with virtual zoom for the images was set to 2.74.
Identical intensities and settings were maintained during imaging of each series. Pearson correlation was derived by taking ⬎5

different images per condition and defining regions as cells. In
conditions with aggregates, only cells with inclusions were analyzed. Pearson values were calculated by the NIS elements colocalization function.
ELISA
ELISA analysis of ␣-syn was performed as previously
described with minor modifications (52). Costar 96 half-well
plates were incubated with Syn211 antibody (Santa Cruz Biotechnology, Inc.) diluted 1:200 in carbonate coating buffer and
incubated at 4 °C overnight. Plates were washed five times with
PBS/Tween 20 (0.05%) (PBS-T) and blocked with 2% BSA/PBS
for 2 h at 37 °C. After five more washes with PBS-T, samples
were diluted in PBS-T (with 0.6% SDS) and protease inhibitor
(Sigma), and then incubated overnight at 4 °C with rocking.
Standard curve samples were prepared in equivalent concentrations of SDS from recombinant ␣-syn monomer. All standards and samples were run in duplicate. After 5 washes of
PBS-T, polyclonal capture antibody FL-140 (Santa Cruz Biotechnology, Inc.) was diluted 1:200 in 0.05% BSA in PBS-T and
added to each well. Samples were incubated for 2 h at 37 °C.
After 5 washes in PBS-T, biotinylated anti-rabbit secondary
horseradish peroxidase antibody (Jackson ImmunoResearch)
was diluted 1:800 in 1% BSA/PBS-T and incubated in the dark
for 1.5 h at room temperature. After 5 washes, the plate was
developed with super slow 3,3⬘5,5⬘-tetramethylbenzidine (Sigma)
and absorbance was determined at 650 nm on a Bio-Tek Synergy 2
plate reader after 45 s of shaking.
Immunoblotting
For brain tissue assessment, samples were sonicated for 3
min at 65A (QSonica S-4000). After a pulse spin, for insoluble
samples, 4⫻ sample buffer (Bio-Rad) with ␤-mercaptoethanol
was added to each sample (soluble samples were diluted 1:1
with sample buffer, to reduce distortion from high salt buffer).
Samples were heated at 95 °C ⫻ 5 min, then quenched on ice.
After a pulse spin, samples were loaded and run on SDS-PAGE
using a 4 –20% Tris glycine TGX gel (Bio-Rad) at 100 V ⫻ 1.5 h.
After three 5-min rinses in transfer buffer, they were transferred onto nitrocellulose, 0.2 m (Bio-Rad), at 150 mA for
3.5 h on ice. Ponceau was used to visualize transfer. Blots were
washed three times for 5 min with T-TBS (TBS with 0.1%
Tween 20) and blocked for 30 min with 5% milk in T-TBS.
Primary antibody incubation was done overnight at 4 °C in 5%
milk in T-TBS with the following (anti-synuclein Clone 42 BD
Bioscience, pSer-129 EP1536Y Abcam). After three 5-min
washes in T-TBS, blots were incubated in secondary antimouse horseradish peroxidase (Invitrogen) at 1:10,000 in 5%
milk with T-TBS. After another wash as above, blots were visualized with ECL plus substrate (Pierce) and imaged on a BioRad imager with quantification by Image Lab.
For serial seeding and extraction experiments (G1 and G2
cell extraction), ␣-syn-CFP/YFP cells were plated on 12-well
plates at a density of 260,000 cells/well and seeded 18 h later as
described above. Three days after seeding, cells were collected
and lysed by sonication for 1 min at 65A, then serially extracted
through high salt buffer, 1% Triton X-100 and a series of TBS
washes interspersed with centrifugation at 100,000 ⫻ g as
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initial seeding as above, cells were incubated for 72 h and subsequently lysed by sonication and serially extracted through the
same buffer and centrifugation steps as above. BCA assay
was performed on the soluble and insoluble cell extracts and
protein concentrations were calculated. Equivalent concentrations of lysate from cells not overexpressing ␣-syn and
lysate from biosensor cells expressing ␣-syn-CFP/YFP, were
added when seeding the naive population of biosensor cells.
After 72 h, cells were fixed with 4% paraformaldehyde (EMS)
for 15 min and washed with Dulbecco’s PBS three times.
They were then mounted on slides using Fluoromount G
with DAPI (Southern Biotechnology).
For photographs, cells were imaged on a Nikon Eclipse
TE2000-U fluorescence microscope using a Nikon Plan Fluor
⫻40/0.75 objective. Metamorph software (Molecular Devices)
was used with Nearest Neighbors algorithm for deconvolution.
For analyses of aggregate percentages in HEK and biosensor
cells, cells were imaged on a Zeiss microscope and fields
throughout each slide were selected by randomly visualizing
fields with ⬎20 DAPI⫹ nuclei at ⫻60. DAPI was used to quantify the total number of cells, and aggregates were counted
under a FITC fluorescent channel (Chroma FITC filter set:
excitation 480 ⫾ 20 nm, emission 535 ⫾ 25 nm and Chroma
DAPI filter set: excitation 350 ⫾ 25 nm, emission 460 ⫾ 25 nm).
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described above. Instead of Dounce homogenization, trituration was used to resuspend the pellet after each spin. BCA
quantification of the soluble and insoluble cell extracts was performed. Equal amounts of extract (30 g for insoluble fractions
and 10 g for soluble fractions) were prepared and diluted in
TBS with protease inhibitor (Sigma) to equal volumes, then
seeded onto G2 cells plated at equivalent density in 12-well
plates. These were then similarly collected and serially extracted into soluble and insoluble fractions as above.
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